studynumber,id,arm,year,drug,n,FullStudyName,corr_auth,corr_auth_email,other_email,answer_after_1_mail,bibkey,treatment,index,val
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,prolactinm,0.57913
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,prolactinm,1.95884955752212
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,prolactinm,16
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,prolactinm,43
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,prolactinm,-16.9
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,prolactinm,-20.6
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,prolactinm,-18.2650641025641
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,prolactinm,-0.47
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,prolactinm,33.02
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,prolactinm,-2.64
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,prolactinm,-1.26042857142857
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,prolactinm,-2.95
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,prolactinm,-0.701617647058824
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,prolactinm,-27.79
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,prolactinm,-15.5618803418803
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,prolactinm,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,prolactinm,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,prolactinm,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,prolactinm,-9.68
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,prolactinm,-13.06
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,prolactinm,-2.7
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,prolactinm,-7.08631578928421
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,prolactinm,-4.54
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,prolactinm,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,prolactinm,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,prolactinm,-6.06
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,prolactinm,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,prolactinm,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,prolactinm,-11.35111672
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,prolactinm,24.81832867
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,prolactinm,-14.6445914486986
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,prolactinm,45.74
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,prolactinm,-3.39
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,prolactinm,1.59
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,prolactinm,-9.43
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,prolactinm,2.8
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,prolactinm,-19.2
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,prolactinm,-13.2
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,prolactinm,16
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,prolactinm,-2
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,prolactinm,19.7
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,prolactinm,-2.8
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,prolactinm,5.7
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,prolactinm,-0.7
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,prolactinm,4.6
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,prolactinm,4.93
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,prolactinm,-3.78
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,prolactinm,-2.52
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,prolactinm,5.02
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,prolactinm,6.43
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,prolactinm,-3.15
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,prolactinm,-3.43
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,prolactinm,4.55
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,prolactinm,14.01
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,prolactinm,-4.95
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,prolactinm,-5
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,prolactinm,-5
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,prolactinm,-3
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,prolactinm,-2
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,prolactinm,-5
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,prolactinm,27.81
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,prolactinm,-0.96
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinm,1.9
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,prolactinm,-6.3
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinm,2.6
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,prolactinm,21.96
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,prolactinm,-7.42
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,prolactinm,-7.9
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,prolactinm,35.8
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,prolactinm,51.4
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,prolactinm,-0.1
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,prolactinm,-9.8
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,prolactinm,-6.62
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,prolactinm,-4.5
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,prolactinm,23.1
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,prolactinm,1.8
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,prolactinm,-13.8
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,prolactinm,-4.3
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,prolactinm,34.5
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,prolactinm,
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,prolactinm,
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,prolactinm,
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,prolactinm,-2.7
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,prolactinm,-6.9
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,prolactinm,-6.55
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,prolactinm,-6.84376693766938
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,prolactinm,13.7
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,prolactinm,14.9
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,prolactinm,72.34
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,prolactinm,-24.11
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,prolactinm,-20.58
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,prolactinm,-22.09
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,prolactinm,-13.34
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,prolactinm,0
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,prolactinm,34
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,prolactinm,-12.54
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,prolactinm,-9.47
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,prolactinm,47.55
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,prolactinm,15.2
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,prolactinm,60.18
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,prolactinm,19.31
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,prolactinm,-9.18
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,prolactinm,-16.22
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,prolactinm,-3.9
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,prolactinm,58.74
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,prolactinm,-1.91
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,prolactinm,-6.5
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,prolactinm,0.1
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,prolactinm,47.9
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,prolactinm,22.5
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,prolactinm,-6
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,prolactinm,0
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,prolactinm,13.6
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,prolactinm,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,prolactinm,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,prolactinm,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,prolactinm,
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,prolactinm,
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,prolactinm,1.99
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,prolactinm,-1.345
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,prolactinm,18.3
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,prolactinm,-19
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,prolactinm,-14.9
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,prolactinm,18.39
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,prolactinm,9.39
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,prolactinm,21.8
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,prolactinm,-0.2
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,prolactinm,1.2
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,prolactinm,13.36
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,prolactinm,1.61
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,prolactinm,4.6
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,prolactinm,-8.2
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,prolactinm,-7.2
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,prolactinm,2.64
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,prolactinm,-4.81
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,prolactinm,10.62
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,prolactinm,25.85
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,prolactinm,20.01
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,prolactinm,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,prolactinm,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,prolactinm,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,prolactinm,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,prolactinm,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,prolactinsd,14.208910221359
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,prolactinsd,16.4342976272031
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,prolactinsd,6
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,prolactinsd,5
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,prolactinsd,37.2
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,prolactinsd,32.2
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,prolactinsd,47.5604244282025
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,prolactinsd,4.33
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,prolactinsd,42.74
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,prolactinsd,14.51
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,prolactinsd,9.64660257525405
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,prolactinsd,20.49
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,prolactinsd,19.5427054324245
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,prolactinsd,46.25
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,prolactinsd,44.6760325318744
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,prolactinsd,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,prolactinsd,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,prolactinsd,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,prolactinsd,19.9
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,prolactinsd,36.59
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,prolactinsd,18.99
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,prolactinsd,28.5658173
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,prolactinsd,33.6
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,prolactinsd,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,prolactinsd,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,prolactinsd,36.7063236773344
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,prolactinsd,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,prolactinsd,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,prolactinsd,36.7063236773344
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,prolactinsd,36.7063236773344
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,prolactinsd,36.7063236773344
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,prolactinsd,44.96
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,prolactinsd,22.31
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,prolactinsd,18.43
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,prolactinsd,19.1
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,prolactinsd,59.11
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,prolactinsd,43.73
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,prolactinsd,39.72
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,prolactinsd,47.1
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,prolactinsd,9.02
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,prolactinsd,32.96
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,prolactinsd,9.09
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,prolactinsd,24.59
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,prolactinsd,8.97
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,prolactinsd,16.19
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,prolactinsd,30.24
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,prolactinsd,23.32
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,prolactinsd,16.88
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,prolactinsd,12.16
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,prolactinsd,22.5
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,prolactinsd,19.4
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,prolactinsd,16.37
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,prolactinsd,26.84
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,prolactinsd,35.96
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,prolactinsd,22.45
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,prolactinsd,40.35
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,prolactinsd,26.32
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,prolactinsd,26.98
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,prolactinsd,17.4
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,prolactinsd,20.6
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,prolactinsd,55.0456553262057
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,prolactinsd,55.0456553262057
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinsd,26
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,prolactinsd,22.4
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinsd,26.7
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,prolactinsd,42.97
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,prolactinsd,25.16
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,prolactinsd,22.6
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,prolactinsd,49.4
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,prolactinsd,65.6
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,prolactinsd,10.89
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,prolactinsd,32.63
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,prolactinsd,28.91
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,prolactinsd,16.7
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,prolactinsd,35.2
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,prolactinsd,18.5
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,prolactinsd,41.2
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,prolactinsd,22.6
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,prolactinsd,44.2
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,prolactinsd,
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,prolactinsd,
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,prolactinsd,
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,prolactinsd,15.7
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,prolactinsd,17.25
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,prolactinsd,16.14
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,prolactinsd,21.9994409736783
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,prolactinsd,12.2
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,prolactinsd,11.6
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,prolactinsd,58.15
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,prolactinsd,50.02
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,prolactinsd,47.42
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,prolactinsd,30.41
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,prolactinsd,30.41
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,prolactinsd,74.9834325587939
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,prolactinsd,74.9834325587939
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,prolactinsd,43.44
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,prolactinsd,44.69
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,prolactinsd,47.73
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,prolactinsd,18.94
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,prolactinsd,59.44
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,prolactinsd,16.2
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,prolactinsd,11.7
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,prolactinsd,19.685
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,prolactinsd,15.31
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,prolactinsd,58.67
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,prolactinsd,27.69
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,prolactinsd,24.3
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,prolactinsd,24.8
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,prolactinsd,24.6
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,prolactinsd,49.77
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,prolactinsd,36.7063236773344
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,prolactinsd,36.7063236773344
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,prolactinsd,36.7063236773344
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,prolactinsd,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,prolactinsd,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,prolactinsd,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,prolactinsd,
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,prolactinsd,
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,prolactinsd,18.88
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,prolactinsd,18.88
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,prolactinsd,18.88
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,prolactinsd,13.96
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,prolactinsd,14.34
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,prolactinsd,10.24
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,prolactinsd,6.38
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,prolactinsd,18.61
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,prolactinsd,36.7063236773344
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,prolactinsd,36.7063236773344
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,prolactinsd,19.12
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,prolactinsd,4.61
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,prolactinsd,7.5
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,prolactinsd,5.97
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,prolactinsd,5.97
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,prolactinsd,23.17
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,prolactinsd,23.87
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,prolactinsd,7.34
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,prolactinsd,18.74
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,prolactinsd,20.35
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,prolactinsd,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,prolactinsd,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,prolactinsd,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,prolactinsd,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,prolactinsd,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,prolactinn,115
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,prolactinn,226
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,prolactinn,31
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,prolactinn,55
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,prolactinn,153
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,prolactinn,152
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,prolactinn,312
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,prolactinn,85
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,prolactinn,82
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,prolactinn,165
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,prolactinn,350
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,prolactinn,168
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,prolactinn,340
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,prolactinn,174
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,prolactinn,351
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,prolactinn,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,prolactinn,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,prolactinn,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,prolactinn,50
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,prolactinn,93
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,prolactinn,90
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,prolactinn,95
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,prolactinn,112
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,prolactinn,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,prolactinn,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,prolactinn,93
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,prolactinn,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,prolactinn,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,prolactinn,151
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,prolactinn,140
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,prolactinn,438
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,prolactinn,77
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,prolactinn,80
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,prolactinn,62
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,prolactinn,122
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,prolactinn,106
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,prolactinn,114
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,prolactinn,203
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,prolactinn,76
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,prolactinn,39
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,prolactinn,60
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,prolactinn,69
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,prolactinn,125
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,prolactinn,77
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,prolactinn,76
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,prolactinn,361
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,prolactinn,122
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,prolactinn,114
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,prolactinn,121
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,prolactinn,234
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,prolactinn,111
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,prolactinn,107
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,prolactinn,225
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,prolactinn,59
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,prolactinn,64
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,prolactinn,194
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,prolactinn,94
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,prolactinn,94
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,prolactinn,86
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,prolactinn,81
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,prolactinn,116
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,prolactinn,114
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinn,134
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,prolactinn,128
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinn,266
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,prolactinn,206
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,prolactinn,107
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,prolactinn,95
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,prolactinn,214
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,prolactinn,60
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,prolactinn,54
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,prolactinn,267
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,prolactinn,84
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,prolactinn,96
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,prolactinn,88
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,prolactinn,89
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,prolactinn,97
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,prolactinn,96
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,prolactinn,80
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,prolactinn,
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,prolactinn,
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,prolactinn,
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,prolactinn,111
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,prolactinn,109
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,prolactinn,92
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,prolactinn,369
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,prolactinn,109
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,prolactinn,123
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,prolactinn,117
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,prolactinn,118
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,prolactinn,470
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,prolactinn,203
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,prolactinn,107
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,prolactinn,149
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,prolactinn,154
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,prolactinn,120
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,prolactinn,125
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,prolactinn,114
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,prolactinn,105
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,prolactinn,222
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,prolactinn,105
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,prolactinn,33
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,prolactinn,62
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,prolactinn,60
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,prolactinn,56
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,prolactinn,58
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,prolactinn,181
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,prolactinn,95
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,prolactinn,91
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,prolactinn,95
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,prolactinn,61
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,prolactinn,64
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,prolactinn,63
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,prolactinn,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,prolactinn,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,prolactinn,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,prolactinn,
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,prolactinn,
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,prolactinn,19
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,prolactinn,56
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,prolactinn,24
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,prolactinn,54
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,prolactinn,57
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,prolactinn,23
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,prolactinn,10
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,prolactinn,46
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,prolactinn,50
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,prolactinn,50
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,prolactinn,63
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,prolactinn,63
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,prolactinn,121
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,prolactinn,46
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,prolactinn,47
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,prolactinn,76
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,prolactinn,39
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,prolactinn,16
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,prolactinn,16
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,prolactinn,15
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,prolactinn,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,prolactinn,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,prolactinn,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,prolactinn,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,prolactinn,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,prolactinsdorigin,original
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,prolactinsdorigin,original
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,prolactinsdorigin,original
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,prolactinsdorigin,original
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,prolactinsdorigin,original
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,prolactinsdorigin,original
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,prolactinsdorigin,original
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,prolactinsdorigin,original
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,prolactinsdorigin,original
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,prolactinsdorigin,original
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,prolactinsdorigin,original
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,prolactinsdorigin,original
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,prolactinsdorigin,original
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,prolactinsdorigin,original
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,prolactinsdorigin,original
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,prolactinsdorigin,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,prolactinsdorigin,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,prolactinsdorigin,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,prolactinsdorigin,original
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,prolactinsdorigin,original
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,prolactinsdorigin,original
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,prolactinsdorigin,original
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,prolactinsdorigin,original
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,prolactinsdorigin,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,prolactinsdorigin,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,prolactinsdorigin,sd estimated from mean of SDs
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,prolactinsdorigin,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,prolactinsdorigin,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,prolactinsdorigin,sd estimated from mean of SDs
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,prolactinsdorigin,sd estimated from mean of SDs
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,prolactinsdorigin,sd estimated from mean of SDs
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,prolactinsdorigin,original
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,prolactinsdorigin,original
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,prolactinsdorigin,original
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,prolactinsdorigin,original
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,prolactinsdorigin,original
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,prolactinsdorigin,original
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,prolactinsdorigin,original
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,prolactinsdorigin,original
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,prolactinsdorigin,original
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,prolactinsdorigin,original
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,prolactinsdorigin,original
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,prolactinsdorigin,original
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,prolactinsdorigin,original
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,prolactinsdorigin,original
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,prolactinsdorigin,original
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,prolactinsdorigin,original
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,prolactinsdorigin,original
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,prolactinsdorigin,original
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,prolactinsdorigin,original
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,prolactinsdorigin,original
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,prolactinsdorigin,original
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,prolactinsdorigin,original
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,prolactinsdorigin,original
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,prolactinsdorigin,original
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,prolactinsdorigin,original
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,prolactinsdorigin,original
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,prolactinsdorigin,original
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,prolactinsdorigin,original
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,prolactinsdorigin,original
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,prolactinsdorigin,p-value
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,prolactinsdorigin,p-value
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinsdorigin,original
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,prolactinsdorigin,original
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinsdorigin,original
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,prolactinsdorigin,original
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,prolactinsdorigin,original
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,prolactinsdorigin,original
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,prolactinsdorigin,original
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,prolactinsdorigin,original
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,prolactinsdorigin,original
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,prolactinsdorigin,original
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,prolactinsdorigin,original
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,prolactinsdorigin,original
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,prolactinsdorigin,original
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,prolactinsdorigin,original
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,prolactinsdorigin,original
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,prolactinsdorigin,original
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,prolactinsdorigin,original
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,prolactinsdorigin,
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,prolactinsdorigin,
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,prolactinsdorigin,
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,prolactinsdorigin,original
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,prolactinsdorigin,original
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,prolactinsdorigin,original
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,prolactinsdorigin,original
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,prolactinsdorigin,original
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,prolactinsdorigin,original
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,prolactinsdorigin,original
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,prolactinsdorigin,original
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,prolactinsdorigin,original
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,prolactinsdorigin,p-value
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,prolactinsdorigin,p-value
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,prolactinsdorigin,p-value
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,prolactinsdorigin,p-value
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,prolactinsdorigin,
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,prolactinsdorigin,
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,prolactinsdorigin,original
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,prolactinsdorigin,original
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,prolactinsdorigin,original
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,prolactinsdorigin,original
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,prolactinsdorigin,original
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,prolactinsdorigin,original
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,prolactinsdorigin,original
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,prolactinsdorigin,original
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,prolactinsdorigin,original
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,prolactinsdorigin,original
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,prolactinsdorigin,original
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,prolactinsdorigin,original
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,prolactinsdorigin,p-value
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,prolactinsdorigin,sd estimated from mean of SDs
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,prolactinsdorigin,sd estimated from mean of SDs
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,prolactinsdorigin,sd estimated from mean of SDs
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,prolactinsdorigin,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,prolactinsdorigin,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,prolactinsdorigin,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,prolactinsdorigin,
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,prolactinsdorigin,
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,prolactinsdorigin,p-value
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,prolactinsdorigin,p-value
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,prolactinsdorigin,p-value
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,prolactinsdorigin,original
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,prolactinsdorigin,original
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,prolactinsdorigin,original
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,prolactinsdorigin,original
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,prolactinsdorigin,original
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,prolactinsdorigin,sd estimated from mean of SDs
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,prolactinsdorigin,sd estimated from mean of SDs
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,prolactinsdorigin,original
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,prolactinsdorigin,original
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,prolactinsdorigin,original
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,prolactinsdorigin,original
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,prolactinsdorigin,original
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,prolactinsdorigin,original
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,prolactinsdorigin,original
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,prolactinsdorigin,original
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,prolactinsdorigin,original
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,prolactinsdorigin,original
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,prolactinsdorigin,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,prolactinsdorigin,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,prolactinsdorigin,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,prolactinsdorigin,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,prolactinsdorigin,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,prolactinextraction,change
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,prolactinextraction,change
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,prolactinextraction,endpoint
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,prolactinextraction,endpoint
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,prolactinextraction,change
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,prolactinextraction,change
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,prolactinextraction,change
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,prolactinextraction,change
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,prolactinextraction,change
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,prolactinextraction,change
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,prolactinextraction,change
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,prolactinextraction,change
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,prolactinextraction,change
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,prolactinextraction,change
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,prolactinextraction,change
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,prolactinextraction,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,prolactinextraction,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,prolactinextraction,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,prolactinextraction,change
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,prolactinextraction,change
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,prolactinextraction,change
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,prolactinextraction,change
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,prolactinextraction,change
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,prolactinextraction,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,prolactinextraction,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,prolactinextraction,change
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,prolactinextraction,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,prolactinextraction,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,prolactinextraction,change
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,prolactinextraction,change
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,prolactinextraction,change
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,prolactinextraction,change
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,prolactinextraction,change
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,prolactinextraction,change
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,prolactinextraction,change
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,prolactinextraction,change
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,prolactinextraction,change
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,prolactinextraction,change
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,prolactinextraction,change
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,prolactinextraction,change
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,prolactinextraction,change
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,prolactinextraction,change
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,prolactinextraction,change
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,prolactinextraction,change
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,prolactinextraction,change
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,prolactinextraction,change
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,prolactinextraction,change
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,prolactinextraction,change
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,prolactinextraction,change
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,prolactinextraction,change
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,prolactinextraction,change
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,prolactinextraction,change
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,prolactinextraction,change
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,prolactinextraction,change
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,prolactinextraction,change
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,prolactinextraction,change
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,prolactinextraction,change
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,prolactinextraction,change
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,prolactinextraction,change
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,prolactinextraction,change
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,prolactinextraction,change
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,prolactinextraction,change
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinextraction,change
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,prolactinextraction,change
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,prolactinextraction,change
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,prolactinextraction,change
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,prolactinextraction,change
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,prolactinextraction,change
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,prolactinextraction,change
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,prolactinextraction,change
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,prolactinextraction,change
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,prolactinextraction,change
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,prolactinextraction,change
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,prolactinextraction,change
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,prolactinextraction,change
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,prolactinextraction,change
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,prolactinextraction,change
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,prolactinextraction,change
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,prolactinextraction,change
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,prolactinextraction,
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,prolactinextraction,
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,prolactinextraction,
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,prolactinextraction,change
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,prolactinextraction,change
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,prolactinextraction,change
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,prolactinextraction,change
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,prolactinextraction,endpoint
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,prolactinextraction,endpoint
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,prolactinextraction,endpoint
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,prolactinextraction,change
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,prolactinextraction,change
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,prolactinextraction,change
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,prolactinextraction,change
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,prolactinextraction,change
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,prolactinextraction,change
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,prolactinextraction,change
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,prolactinextraction,change
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,prolactinextraction,change
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,prolactinextraction,endpoint
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,prolactinextraction,endpoint
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,prolactinextraction,endpoint
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,prolactinextraction,change
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,prolactinextraction,change
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,prolactinextraction,change
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,prolactinextraction,change
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,prolactinextraction,change
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,prolactinextraction,change
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,prolactinextraction,change
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,prolactinextraction,change
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,prolactinextraction,change
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,prolactinextraction,change
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,prolactinextraction,change
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,prolactinextraction,change
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,prolactinextraction,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,prolactinextraction,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,prolactinextraction,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,prolactinextraction,
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,prolactinextraction,
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,prolactinextraction,change
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,prolactinextraction,change
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,prolactinextraction,change
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,prolactinextraction,change
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,prolactinextraction,change
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,prolactinextraction,endpoint
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,prolactinextraction,endpoint
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,prolactinextraction,endpoint
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,prolactinextraction,change
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,prolactinextraction,change
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,prolactinextraction,change
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,prolactinextraction,change
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,prolactinextraction,change
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,prolactinextraction,change
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,prolactinextraction,change
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,prolactinextraction,change
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,prolactinextraction,change
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,prolactinextraction,endpoint
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,prolactinextraction,endpoint
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,prolactinextraction,endpoint
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,prolactinextraction,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,prolactinextraction,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,prolactinextraction,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,prolactinextraction,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,prolactinextraction,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,qtcm,
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,qtcm,
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,qtcm,
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,qtcm,
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,qtcm,
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,qtcm,
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,qtcm,
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,qtcm,
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,qtcm,
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,qtcm,3.5
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,qtcm,1.21420454545455
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,qtcm,0.9
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,qtcm,0.222448979591837
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,qtcm,
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,qtcm,
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,qtcm,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,qtcm,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,qtcm,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,qtcm,
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,qtcm,
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,qtcm,
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,qtcm,
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,qtcm,
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,qtcm,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,qtcm,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,qtcm,
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,qtcm,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,qtcm,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,qtcm,-1.4
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,qtcm,5.1
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,qtcm,-1.9675799086758
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,qtcm,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,qtcm,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,qtcm,
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,qtcm,
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,qtcm,
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,qtcm,
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,qtcm,
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,qtcm,-0.1
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,qtcm,2.2
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,qtcm,2.1
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,qtcm,-1.8
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,qtcm,-0.4
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,qtcm,5.4
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,qtcm,3.3
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,qtcm,2
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,qtcm,2.2
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,qtcm,9
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,qtcm,10
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,qtcm,4.4
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,qtcm,7.6
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,qtcm,10.4
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,qtcm,2.9
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,qtcm,3.03
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,qtcm,6.1
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,qtcm,
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,qtcm,
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,qtcm,
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,qtcm,
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,qtcm,
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,qtcm,
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,qtcm,
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcm,6.1
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,qtcm,-2
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcm,7.2
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,qtcm,
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,qtcm,
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,qtcm,
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,qtcm,
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,qtcm,
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,qtcm,
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,qtcm,1.4
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,qtcm,-2.7
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,qtcm,-0.3
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,qtcm,1.4
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,qtcm,0.1
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,qtcm,1.2
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,qtcm,5
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,qtcm,2.4
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,qtcm,1.1
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,qtcm,-2.5
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,qtcm,6.1
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,qtcm,
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,qtcm,
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,qtcm,-1.79
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,qtcm,1.2575
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,qtcm,
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,qtcm,
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,qtcm,
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,qtcm,
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,qtcm,
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,qtcm,
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,qtcm,
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,qtcm,
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,qtcm,
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,qtcm,
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,qtcm,
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,qtcm,
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,qtcm,0.5
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,qtcm,0.35
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,qtcm,1.9
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,qtcm,4.16
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,qtcm,1.61
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,qtcm,-1.6
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,qtcm,4.4
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,qtcm,4.6
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,qtcm,-0.67
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,qtcm,-2.18
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,qtcm,6.31
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,qtcm,1.67
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,qtcm,-6.6
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,qtcm,-4.5
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,qtcm,-0.7
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,qtcm,406.2
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,qtcm,422.6
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,qtcm,410.2
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,qtcm,413.3
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,qtcm,417.2
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,qtcm,-5
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,qtcm,2.86
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,qtcm,4
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,qtcm,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,qtcm,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,qtcm,20.85
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,qtcm,-6.9
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,qtcm,1.48
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,qtcm,
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,qtcm,
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,qtcm,1.76
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,qtcm,-1.77
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,qtcm,2.73
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,qtcm,-0.1
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,qtcm,7.2
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,qtcm,20.04
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,qtcm,-0.34
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,qtcm,-0.85
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,qtcm,-5.23
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,qtcm,24.84
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,qtcm,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,qtcm,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,qtcm,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,qtcm,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,qtcm,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,qtcsd,
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,qtcsd,
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,qtcsd,
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,qtcsd,
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,qtcsd,
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,qtcsd,
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,qtcsd,
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,qtcsd,
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,qtcsd,
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,qtcsd,18
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,qtcsd,17.513891319178
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,qtcsd,18.5
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,qtcsd,15.7762754256417
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,qtcsd,
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,qtcsd,
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,qtcsd,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,qtcsd,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,qtcsd,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,qtcsd,
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,qtcsd,
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,qtcsd,
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,qtcsd,
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,qtcsd,
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,qtcsd,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,qtcsd,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,qtcsd,
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,qtcsd,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,qtcsd,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,qtcsd,24.757979667836
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,qtcsd,24.757979667836
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,qtcsd,24.757979667836
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,qtcsd,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,qtcsd,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,qtcsd,
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,qtcsd,
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,qtcsd,
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,qtcsd,
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,qtcsd,
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,qtcsd,22.09
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,qtcsd,21.24
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,qtcsd,20.3
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,qtcsd,19
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,qtcsd,21.71
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,qtcsd,20
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,qtcsd,20.4
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,qtcsd,22.6
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,qtcsd,22.8
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,qtcsd,20.6
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,qtcsd,21.6
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,qtcsd,20.6
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,qtcsd,19
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,qtcsd,17.6
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,qtcsd,20.67
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,qtcsd,26.48
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,qtcsd,20.39
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,qtcsd,
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,qtcsd,
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,qtcsd,
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,qtcsd,
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,qtcsd,
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,qtcsd,
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,qtcsd,
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcsd,18.6
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,qtcsd,18.2
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcsd,20.2
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,qtcsd,
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,qtcsd,
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,qtcsd,
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,qtcsd,
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,qtcsd,
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,qtcsd,
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,qtcsd,20.4
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,qtcsd,16.6
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,qtcsd,19.3
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,qtcsd,20.5
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,qtcsd,20.2
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,qtcsd,19.6
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,qtcsd,19
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,qtcsd,20.2
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,qtcsd,22.9
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,qtcsd,21.3
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,qtcsd,20.6
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,qtcsd,
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,qtcsd,
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,qtcsd,24.757979667836
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,qtcsd,24.757979667836
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,qtcsd,
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,qtcsd,
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,qtcsd,
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,qtcsd,
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,qtcsd,
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,qtcsd,
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,qtcsd,
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,qtcsd,
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,qtcsd,
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,qtcsd,
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,qtcsd,
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,qtcsd,
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,qtcsd,15.37
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,qtcsd,13.34
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,qtcsd,16.7
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,qtcsd,24.757979667836
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,qtcsd,24.757979667836
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,qtcsd,18
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,qtcsd,16.8
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,qtcsd,18.5
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,qtcsd,22.4
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,qtcsd,22.6
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,qtcsd,22.4
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,qtcsd,24.757979667836
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,qtcsd,24
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,qtcsd,24
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,qtcsd,24
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,qtcsd,22.1
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,qtcsd,29.59
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,qtcsd,19.4
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,qtcsd,40.7
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,qtcsd,23.6
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,qtcsd,24.757979667836
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,qtcsd,24.757979667836
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,qtcsd,24.757979667836
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,qtcsd,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,qtcsd,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,qtcsd,31
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,qtcsd,19.13
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,qtcsd,23.3
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,qtcsd,
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,qtcsd,
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,qtcsd,25.52
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,qtcsd,19.38
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,qtcsd,27.43
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,qtcsd,24.757979667836
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,qtcsd,24.757979667836
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,qtcsd,21.72
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,qtcsd,11.33
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,qtcsd,24.18
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,qtcsd,29.51
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,qtcsd,28.53
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,qtcsd,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,qtcsd,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,qtcsd,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,qtcsd,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,qtcsd,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,qtcn,
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,qtcn,
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,qtcn,
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,qtcn,
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,qtcn,
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,qtcn,
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,qtcn,
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,qtcn,
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,qtcn,
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,qtcn,168
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,qtcn,352
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,qtcn,170
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,qtcn,343
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,qtcn,
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,qtcn,
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,qtcn,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,qtcn,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,qtcn,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,qtcn,
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,qtcn,
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,qtcn,
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,qtcn,
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,qtcn,
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,qtcn,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,qtcn,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,qtcn,
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,qtcn,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,qtcn,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,qtcn,151
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,qtcn,140
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,qtcn,438
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,qtcn,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,qtcn,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,qtcn,
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,qtcn,
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,qtcn,
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,qtcn,
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,qtcn,
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,qtcn,98
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,qtcn,49
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,qtcn,66
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,qtcn,68
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,qtcn,132
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,qtcn,90
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,qtcn,90
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,qtcn,359
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,qtcn,120
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,qtcn,109
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,qtcn,121
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,qtcn,227
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,qtcn,113
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,qtcn,107
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,qtcn,225
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,qtcn,60
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,qtcn,64
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,qtcn,
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,qtcn,
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,qtcn,
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,qtcn,
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,qtcn,
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,qtcn,
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,qtcn,
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcn,148
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,qtcn,141
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcn,288
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,qtcn,
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,qtcn,
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,qtcn,
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,qtcn,
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,qtcn,
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,qtcn,
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,qtcn,213
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,qtcn,66
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,qtcn,116
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,qtcn,110
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,qtcn,113
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,qtcn,147
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,qtcn,145
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,qtcn,136
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,qtcn,138
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,qtcn,143
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,qtcn,323
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,qtcn,
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,qtcn,
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,qtcn,117
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,qtcn,447
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,qtcn,
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,qtcn,
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,qtcn,
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,qtcn,
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,qtcn,
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,qtcn,
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,qtcn,
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,qtcn,
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,qtcn,
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,qtcn,
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,qtcn,
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,qtcn,
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,qtcn,105
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,qtcn,222
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,qtcn,105
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,qtcn,28
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,qtcn,27
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,qtcn,58
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,qtcn,57
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,qtcn,57
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,qtcn,194
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,qtcn,103
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,qtcn,95
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,qtcn,104
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,qtcn,57
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,qtcn,61
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,qtcn,57
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,qtcn,75
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,qtcn,156
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,qtcn,79
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,qtcn,84
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,qtcn,102
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,qtcn,51
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,qtcn,105
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,qtcn,52
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,qtcn,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,qtcn,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,qtcn,117
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,qtcn,60
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,qtcn,176
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,qtcn,
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,qtcn,
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,qtcn,54
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,qtcn,54
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,qtcn,109
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,qtcn,55
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,qtcn,54
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,qtcn,91
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,qtcn,41
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,qtcn,78
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,qtcn,90
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,qtcn,93
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,qtcn,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,qtcn,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,qtcn,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,qtcn,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,qtcn,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,qtcsdorigin,
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,qtcsdorigin,
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,qtcsdorigin,
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,qtcsdorigin,
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,qtcsdorigin,
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,qtcsdorigin,
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,qtcsdorigin,
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,qtcsdorigin,
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,qtcsdorigin,
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,qtcsdorigin,original
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,qtcsdorigin,original
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,qtcsdorigin,original
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,qtcsdorigin,original
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,qtcsdorigin,
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,qtcsdorigin,
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,qtcsdorigin,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,qtcsdorigin,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,qtcsdorigin,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,qtcsdorigin,
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,qtcsdorigin,
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,qtcsdorigin,
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,qtcsdorigin,
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,qtcsdorigin,
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,qtcsdorigin,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,qtcsdorigin,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,qtcsdorigin,
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,qtcsdorigin,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,qtcsdorigin,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,qtcsdorigin,sd estimated from mean of SDs
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,qtcsdorigin,sd estimated from mean of SDs
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,qtcsdorigin,sd estimated from mean of SDs
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,qtcsdorigin,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,qtcsdorigin,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,qtcsdorigin,
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,qtcsdorigin,
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,qtcsdorigin,
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,qtcsdorigin,
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,qtcsdorigin,
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,qtcsdorigin,original
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,qtcsdorigin,original
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,qtcsdorigin,original
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,qtcsdorigin,original
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,qtcsdorigin,original
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,qtcsdorigin,original
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,qtcsdorigin,original
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,qtcsdorigin,original
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,qtcsdorigin,original
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,qtcsdorigin,original
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,qtcsdorigin,original
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,qtcsdorigin,original
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,qtcsdorigin,original
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,qtcsdorigin,original
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,qtcsdorigin,original
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,qtcsdorigin,original
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,qtcsdorigin,original
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,qtcsdorigin,
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,qtcsdorigin,
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,qtcsdorigin,
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,qtcsdorigin,
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,qtcsdorigin,
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,qtcsdorigin,
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,qtcsdorigin,
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcsdorigin,original
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,qtcsdorigin,original
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcsdorigin,original
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,qtcsdorigin,
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,qtcsdorigin,
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,qtcsdorigin,
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,qtcsdorigin,
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,qtcsdorigin,
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,qtcsdorigin,
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,qtcsdorigin,original
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,qtcsdorigin,original
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,qtcsdorigin,original
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,qtcsdorigin,original
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,qtcsdorigin,original
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,qtcsdorigin,original
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,qtcsdorigin,original
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,qtcsdorigin,original
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,qtcsdorigin,original
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,qtcsdorigin,original
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,qtcsdorigin,original
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,qtcsdorigin,
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,qtcsdorigin,
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,qtcsdorigin,sd estimated from mean of SDs
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,qtcsdorigin,sd estimated from mean of SDs
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,qtcsdorigin,
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,qtcsdorigin,
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,qtcsdorigin,
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,qtcsdorigin,
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,qtcsdorigin,
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,qtcsdorigin,
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,qtcsdorigin,
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,qtcsdorigin,
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,qtcsdorigin,
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,qtcsdorigin,
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,qtcsdorigin,
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,qtcsdorigin,
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,qtcsdorigin,original
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,qtcsdorigin,original
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,qtcsdorigin,original
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,qtcsdorigin,sd estimated from mean of SDs
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,qtcsdorigin,sd estimated from mean of SDs
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,qtcsdorigin,original
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,qtcsdorigin,original
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,qtcsdorigin,original
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,qtcsdorigin,original
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,qtcsdorigin,original
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,qtcsdorigin,original
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,qtcsdorigin,sd estimated from mean of SDs
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,qtcsdorigin,p-value
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,qtcsdorigin,p-value
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,qtcsdorigin,p-value
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,qtcsdorigin,original
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,qtcsdorigin,original
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,qtcsdorigin,original
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,qtcsdorigin,original
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,qtcsdorigin,original
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,qtcsdorigin,sd estimated from mean of SDs
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,qtcsdorigin,sd estimated from mean of SDs
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,qtcsdorigin,sd estimated from mean of SDs
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,qtcsdorigin,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,qtcsdorigin,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,qtcsdorigin,original
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,qtcsdorigin,original
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,qtcsdorigin,original
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,qtcsdorigin,
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,qtcsdorigin,
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,qtcsdorigin,original
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,qtcsdorigin,original
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,qtcsdorigin,original
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,qtcsdorigin,sd estimated from mean of SDs
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,qtcsdorigin,sd estimated from mean of SDs
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,qtcsdorigin,original
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,qtcsdorigin,original
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,qtcsdorigin,original
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,qtcsdorigin,original
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,qtcsdorigin,original
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,qtcsdorigin,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,qtcsdorigin,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,qtcsdorigin,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,qtcsdorigin,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,qtcsdorigin,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,qtcextraction,
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,qtcextraction,
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,qtcextraction,
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,qtcextraction,
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,qtcextraction,
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,qtcextraction,
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,qtcextraction,
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,qtcextraction,
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,qtcextraction,
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,qtcextraction,change
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,qtcextraction,change
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,qtcextraction,change
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,qtcextraction,change
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,qtcextraction,
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,qtcextraction,
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,qtcextraction,
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,qtcextraction,
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,qtcextraction,
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,qtcextraction,
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,qtcextraction,
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,qtcextraction,
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,qtcextraction,
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,qtcextraction,
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,qtcextraction,
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,qtcextraction,
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,qtcextraction,
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,qtcextraction,
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,qtcextraction,
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,qtcextraction,change
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,qtcextraction,change
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,qtcextraction,change
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,qtcextraction,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,qtcextraction,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,qtcextraction,
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,qtcextraction,
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,qtcextraction,
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,qtcextraction,
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,qtcextraction,
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,qtcextraction,change
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,qtcextraction,change
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,qtcextraction,change
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,qtcextraction,change
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,qtcextraction,change
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,qtcextraction,change
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,qtcextraction,change
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,qtcextraction,change
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,qtcextraction,change
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,qtcextraction,change
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,qtcextraction,change
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,qtcextraction,change
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,qtcextraction,change
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,qtcextraction,change
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,qtcextraction,change
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,qtcextraction,change
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,qtcextraction,change
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,qtcextraction,
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,qtcextraction,
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,qtcextraction,
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,qtcextraction,
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,qtcextraction,
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,qtcextraction,
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,qtcextraction,
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcextraction,change
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,qtcextraction,change
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,qtcextraction,change
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,qtcextraction,
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,qtcextraction,
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,qtcextraction,
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,qtcextraction,
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,qtcextraction,
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,qtcextraction,
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,qtcextraction,change
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,qtcextraction,change
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,qtcextraction,change
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,qtcextraction,change
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,qtcextraction,change
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,qtcextraction,change
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,qtcextraction,change
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,qtcextraction,change
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,qtcextraction,change
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,qtcextraction,change
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,qtcextraction,change
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,qtcextraction,
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,qtcextraction,
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,qtcextraction,change
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,qtcextraction,change
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,qtcextraction,
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,qtcextraction,
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,qtcextraction,
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,qtcextraction,
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,qtcextraction,
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,qtcextraction,
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,qtcextraction,
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,qtcextraction,
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,qtcextraction,
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,qtcextraction,
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,qtcextraction,
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,qtcextraction,
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,qtcextraction,change
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,qtcextraction,change
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,qtcextraction,change
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,qtcextraction,change
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,qtcextraction,change
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,qtcextraction,change
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,qtcextraction,change
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,qtcextraction,change
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,qtcextraction,change
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,qtcextraction,change
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,qtcextraction,change
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,qtcextraction,change
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,qtcextraction,change
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,qtcextraction,change
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,qtcextraction,change
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,qtcextraction,endpoint
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,qtcextraction,endpoint
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,qtcextraction,endpoint
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,qtcextraction,endpoint
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,qtcextraction,endpoint
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,qtcextraction,change
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,qtcextraction,change
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,qtcextraction,change
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,qtcextraction,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,qtcextraction,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,qtcextraction,change
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,qtcextraction,change
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,qtcextraction,change
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,qtcextraction,
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,qtcextraction,
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,qtcextraction,change
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,qtcextraction,change
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,qtcextraction,change
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,qtcextraction,change
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,qtcextraction,change
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,qtcextraction,change
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,qtcextraction,change
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,qtcextraction,change
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,qtcextraction,change
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,qtcextraction,change
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,qtcextraction,
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,qtcextraction,
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,qtcextraction,
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,qtcextraction,
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,qtcextraction,
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,weightm,-1.16
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,weightm,-2.68986784140969
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,weightm,0.9
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,weightm,1.5
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,weightm,0.1
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,weightm,0.7
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,weightm,0.699358974358974
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,weightm,0.8
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,weightm,3
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,weightm,0.35
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,weightm,1.706
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,weightm,0.42
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,weightm,1.36546961325967
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,weightm,-1.76
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,weightm,0.617777777777778
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,weightm,1.3
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,weightm,0.3
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,weightm,2.4
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,weightm,0.3
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,weightm,0.2
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,weightm,1.4
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,weightm,0.275510204
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,weightm,0.1
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,weightm,1.1
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,weightm,5.5
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,weightm,2.7368
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,weightm,1.3
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,weightm,5.34
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,weightm,0.5
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,weightm,2
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,weightm,1.26552511415525
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,weightm,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,weightm,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,weightm,1.37
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,weightm,0.19
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,weightm,0.3
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,weightm,0.4
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,weightm,0.7
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,weightm,0.25
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,weightm,0
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,weightm,0.1
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,weightm,0
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,weightm,0
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,weightm,0.5
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,weightm,0.9
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,weightm,0.93
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,weightm,0.3
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,weightm,0.6
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,weightm,4.1
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,weightm,1
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,weightm,0.1
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,weightm,2.1
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,weightm,0.6
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,weightm,0.416
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,weightm,-0.513
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,weightm,0.958653846
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,weightm,0.1
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,weightm,2.2
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,weightm,2.1
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,weightm,-0.2
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,weightm,2.2
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,weightm,0.86
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightm,1.11
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,weightm,0.52
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightm,2.79
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,weightm,1.3
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,weightm,0.3
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,weightm,0.1
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,weightm,0.8
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,weightm,0.5
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,weightm,0.6
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,weightm,1.45
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,weightm,0.1
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,weightm,0.19
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,weightm,0.03
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,weightm,2.13
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,weightm,0
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,weightm,2
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,weightm,2
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,weightm,1
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,weightm,-1
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,weightm,2
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,weightm,0.6
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,weightm,1.6
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,weightm,-0.14
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,weightm,0.901338028169014
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,weightm,-0.8
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,weightm,2.2
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,weightm,1.5
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,weightm,0.48
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,weightm,1.45
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,weightm,0.21
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,weightm,-0.64
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,weightm,0
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,weightm,1.5
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,weightm,-0.7
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,weightm,1.3
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,weightm,0.57
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,weightm,0.4
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,weightm,1.5
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,weightm,2.7
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,weightm,0.74
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,weightm,0
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,weightm,0.15
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,weightm,1.6
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,weightm,0.47
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,weightm,1
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,weightm,-0.3
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,weightm,1.5
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,weightm,0.5
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,weightm,
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,weightm,
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,weightm,
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,weightm,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,weightm,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,weightm,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,weightm,0
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,weightm,0
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,weightm,-0.8
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,weightm,2.45
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,weightm,0.3
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,weightm,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,weightm,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,weightm,
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,weightm,
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,weightm,
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,weightm,0.4
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,weightm,2.2
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,weightm,0.91
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,weightm,-0.42
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,weightm,3.55
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,weightm,0.5
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,weightm,5.5
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,weightm,3.3
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,weightm,0.8
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,weightm,0
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,weightm,0.41
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,weightm,3.4
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,weightm,71
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,weightm,63
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,weightm,67
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,weightm,70
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,weightm,64
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,weightsd,5
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,weightsd,5
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,weightsd,4.4
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,weightsd,2.7
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,weightsd,3.61969389008628
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,weightsd,3.61969389008628
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,weightsd,3.61969389008628
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,weightsd,3.46
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,weightsd,3.69
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,weightsd,3.61969389008628
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,weightsd,3.61969389008628
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,weightsd,3.61969389008628
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,weightsd,3.61969389008628
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,weightsd,2.45
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,weightsd,2.78114857018116
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,weightsd,3.51
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,weightsd,3.52
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,weightsd,3.19
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,weightsd,2.7
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,weightsd,2.3
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,weightsd,4.3
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,weightsd,3.607759812
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,weightsd,2.5
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,weightsd,2.4
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,weightsd,3.8
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,weightsd,3.679814106
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,weightsd,4.58
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,weightsd,5.09
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,weightsd,2.9
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,weightsd,3.2
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,weightsd,3.12396446010505
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,weightsd,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,weightsd,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,weightsd,2.05
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,weightsd,2.1
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,weightsd,3.61969389008628
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,weightsd,3.61969389008628
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,weightsd,3.61969389008628
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,weightsd,2.4
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,weightsd,2.9
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,weightsd,3.09
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,weightsd,3
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,weightsd,4
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,weightsd,3
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,weightsd,3
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,weightsd,2.95
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,weightsd,2.7
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,weightsd,2.7
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,weightsd,4.3
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,weightsd,2.57
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,weightsd,2.5
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,weightsd,3.3
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,weightsd,2.86
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,weightsd,1.819
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,weightsd,2.519
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,weightsd,
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,weightsd,
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,weightsd,
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,weightsd,
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,weightsd,
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,weightsd,4
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,weightsd,4
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightsd,3.61969389008628
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,weightsd,3.61969389008628
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightsd,3.61969389008628
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,weightsd,2.7
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,weightsd,2
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,weightsd,2.2
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,weightsd,2.7
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,weightsd,2.75
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,weightsd,3.09
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,weightsd,5
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,weightsd,2.8
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,weightsd,2.98
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,weightsd,4.82
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,weightsd,3.86
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,weightsd,5
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,weightsd,5
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,weightsd,5
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,weightsd,3
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,weightsd,3
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,weightsd,4
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,weightsd,3.8
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,weightsd,3.4
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,weightsd,3.54
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,weightsd,5.14898445644239
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,weightsd,4.24
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,weightsd,3.94
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,weightsd,3.14
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,weightsd,3.23
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,weightsd,2.6
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,weightsd,3
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,weightsd,2.63
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,weightsd,2
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,weightsd,2
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,weightsd,2.4
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,weightsd,2.8
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,weightsd,2.85
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,weightsd,3.6
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,weightsd,3.74
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,weightsd,4.4
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,weightsd,2
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,weightsd,2
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,weightsd,3.61969389008628
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,weightsd,3.61969389008628
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,weightsd,3.61969389008628
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,weightsd,5
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,weightsd,5
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,weightsd,6
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,weightsd,3.61969389008628
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,weightsd,
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,weightsd,
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,weightsd,
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,weightsd,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,weightsd,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,weightsd,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,weightsd,3.61969389008628
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,weightsd,3.61969389008628
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,weightsd,3.61969389008628
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,weightsd,3.61969389008628
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,weightsd,3.61969389008628
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,weightsd,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,weightsd,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,weightsd,
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,weightsd,
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,weightsd,
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,weightsd,3.1
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,weightsd,4
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,weightsd,3.48
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,weightsd,2.78
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,weightsd,3.93
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,weightsd,5
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,weightsd,5
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,weightsd,6
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,weightsd,6
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,weightsd,3.61969389008628
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,weightsd,3.61969389008628
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,weightsd,3.61969389008628
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,weightsd,8
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,weightsd,8
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,weightsd,4
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,weightsd,5.366184713
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,weightsd,5.366184713
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,weightn,116
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,weightn,227
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,weightn,55
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,weightn,31
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,weightn,153
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,weightn,152
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,weightn,312
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,weightn,85
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,weightn,82
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,weightn,184
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,weightn,370
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,weightn,184
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,weightn,362
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,weightn,174
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,weightn,351
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,weightn,113
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,weightn,101
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,weightn,46
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,weightn,50
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,weightn,93
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,weightn,90
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,weightn,98
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,weightn,112
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,weightn,41
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,weightn,22
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,weightn,93
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,weightn,77
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,weightn,77
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,weightn,151
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,weightn,140
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,weightn,438
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,weightn,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,weightn,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,weightn,62
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,weightn,122
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,weightn,115
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,weightn,123
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,weightn,217
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,weightn,99
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,weightn,50
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,weightn,71
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,weightn,69
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,weightn,137
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,weightn,90
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,weightn,89
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,weightn,364
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,weightn,124
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,weightn,115
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,weightn,122
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,weightn,237
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,weightn,115
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,weightn,111
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,weightn,229
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,weightn,60
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,weightn,64
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,weightn,
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,weightn,
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,weightn,
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,weightn,
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,weightn,
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,weightn,116
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,weightn,114
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightn,150
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,weightn,147
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightn,300
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,weightn,206
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,weightn,107
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,weightn,95
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,weightn,214
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,weightn,64
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,weightn,56
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,weightn,258
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,weightn,80
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,weightn,124
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,weightn,118
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,weightn,121
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,weightn,152
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,weightn,149
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,weightn,146
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,weightn,150
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,weightn,152
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,weightn,366
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,weightn,127
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,weightn,124
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,weightn,108
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,weightn,426
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,weightn,110
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,weightn,115
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,weightn,118
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,weightn,118
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,weightn,470
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,weightn,200
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,weightn,107
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,weightn,140
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,weightn,150
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,weightn,119
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,weightn,123
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,weightn,362
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,weightn,94
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,weightn,188
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,weightn,90
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,weightn,34
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,weightn,63
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,weightn,54
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,weightn,47
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,weightn,46
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,weightn,201
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,weightn,103
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,weightn,99
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,weightn,104
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,weightn,
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,weightn,
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,weightn,
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,weightn,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,weightn,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,weightn,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,weightn,89
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,weightn,104
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,weightn,51
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,weightn,105
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,weightn,52
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,weightn,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,weightn,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,weightn,
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,weightn,
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,weightn,
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,weightn,50
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,weightn,50
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,weightn,67
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,weightn,65
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,weightn,125
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,weightn,55
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,weightn,54
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,weightn,54
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,weightn,48
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,weightn,116
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,weightn,115
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,weightn,117
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,weightn,17
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,weightn,16
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,weightn,17
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,weightn,14
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,weightn,12
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,weightsdorigin,sd estimated from mean of SDs
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,weightsdorigin,sd estimated from mean of SDs
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,weightsdorigin,original
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,weightsdorigin,original
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,weightsdorigin,sd estimated from mean of SDs
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,weightsdorigin,sd estimated from mean of SDs
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,weightsdorigin,sd estimated from mean of SDs
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,weightsdorigin,original
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,weightsdorigin,original
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,weightsdorigin,sd estimated from mean of SDs
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,weightsdorigin,sd estimated from mean of SDs
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,weightsdorigin,sd estimated from mean of SDs
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,weightsdorigin,sd estimated from mean of SDs
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,weightsdorigin,original
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,weightsdorigin,original
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,weightsdorigin,original
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,weightsdorigin,original
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,weightsdorigin,original
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,weightsdorigin,original
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,weightsdorigin,original
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,weightsdorigin,original
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,weightsdorigin,original
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,weightsdorigin,original
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,weightsdorigin,original
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,weightsdorigin,original
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,weightsdorigin,original
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,weightsdorigin,original
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,weightsdorigin,original
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,weightsdorigin,original
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,weightsdorigin,original
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,weightsdorigin,original
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,weightsdorigin,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,weightsdorigin,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,weightsdorigin,original
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,weightsdorigin,original
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,weightsdorigin,sd estimated from mean of SDs
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,weightsdorigin,sd estimated from mean of SDs
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,weightsdorigin,sd estimated from mean of SDs
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,weightsdorigin,original
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,weightsdorigin,original
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,weightsdorigin,original
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,weightsdorigin,original
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,weightsdorigin,original
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,weightsdorigin,original
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,weightsdorigin,original
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,weightsdorigin,original
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,weightsdorigin,original
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,weightsdorigin,original
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,weightsdorigin,original
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,weightsdorigin,original
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,weightsdorigin,original
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,weightsdorigin,original
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,weightsdorigin,original
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,weightsdorigin,
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,weightsdorigin,
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,weightsdorigin,
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,weightsdorigin,
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,weightsdorigin,
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,weightsdorigin,
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,weightsdorigin,
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,weightsdorigin,p-value
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,weightsdorigin,p-value
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightsdorigin,sd estimated from mean of SDs
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,weightsdorigin,sd estimated from mean of SDs
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightsdorigin,sd estimated from mean of SDs
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,weightsdorigin,original
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,weightsdorigin,original
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,weightsdorigin,original
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,weightsdorigin,original
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,weightsdorigin,original
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,weightsdorigin,original
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,weightsdorigin,original
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,weightsdorigin,original
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,weightsdorigin,original
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,weightsdorigin,original
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,weightsdorigin,original
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,weightsdorigin,sd estimated from mean of SDs
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,weightsdorigin,sd estimated from mean of SDs
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,weightsdorigin,sd estimated from mean of SDs
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,weightsdorigin,original
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,weightsdorigin,original
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,weightsdorigin,original
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,weightsdorigin,original
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,weightsdorigin,original
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,weightsdorigin,original
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,weightsdorigin,original
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,weightsdorigin,original
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,weightsdorigin,original
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,weightsdorigin,original
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,weightsdorigin,original
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,weightsdorigin,original
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,weightsdorigin,p-value
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,weightsdorigin,p-value
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,weightsdorigin,p-value
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,weightsdorigin,p-value
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,weightsdorigin,original
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,weightsdorigin,original
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,weightsdorigin,original
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,weightsdorigin,original
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,weightsdorigin,original
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,weightsdorigin,original
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,weightsdorigin,p-value
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,weightsdorigin,p-value
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,weightsdorigin,sd estimated from mean of SDs
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,weightsdorigin,sd estimated from mean of SDs
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,weightsdorigin,sd estimated from mean of SDs
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,weightsdorigin,p-value
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,weightsdorigin,p-value
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,weightsdorigin,p-value
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,weightsdorigin,sd estimated from mean of SDs
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,weightsdorigin,
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,weightsdorigin,
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,weightsdorigin,
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,weightsdorigin,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,weightsdorigin,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,weightsdorigin,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,weightsdorigin,sd estimated from mean of SDs
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,weightsdorigin,sd estimated from mean of SDs
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,weightsdorigin,sd estimated from mean of SDs
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,weightsdorigin,sd estimated from mean of SDs
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,weightsdorigin,sd estimated from mean of SDs
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,weightsdorigin,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,weightsdorigin,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,weightsdorigin,
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,weightsdorigin,
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,weightsdorigin,
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,weightsdorigin,original
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,weightsdorigin,original
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,weightsdorigin,original
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,weightsdorigin,original
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,weightsdorigin,original
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,weightsdorigin,sd estimated from mean of SDs
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,weightsdorigin,sd estimated from mean of SDs
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,weightsdorigin,p-value
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,weightsdorigin,p-value
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,weightsdorigin,sd estimated from mean of SDs
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,weightsdorigin,sd estimated from mean of SDs
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,weightsdorigin,sd estimated from mean of SDs
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,weightsdorigin,p-value
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,weightsdorigin,p-value
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,weightsdorigin,p-value
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,weightsdorigin,p-value
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,weightsdorigin,p-value
4686,Ishigooka 2018,78381,2018,Placebo,116,"Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the japan multicenter, double-blind olanzapine trial. Psychiatry & clinical Neurosciences2001",Dr Tadori,tadori.yoshihiro@otsuka.jp,,,Ishigooka2018,control,weightextraction,change
4686,Ishigooka 2018,78421,2018,Brexpiprazole,228,,,,,,Ishigooka2018,active,weightextraction,change
2798,Litman 2016,7675,2016,Placebo,55,"Litman RE, Smith MA, Doherty JJ et al.AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Abstracts of the 4th Biennial Schizophrenia International Research Conference2016","Dr Litman, Dr Zukin","relitman@cbhhealth.com, stephen.zukin@frx.com",,,Litman2016,control,weightextraction,change
2798,Litman 2016,7676,2016,Risperidone,31,,,,,,Litman2016,active,weightextraction,change
331,NCT01104766a,700,2015,Placebo,153,"Durgam S, Cutler AJ, Lu K et al.Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial. Journal of clinical Psychiatry2015",Dr Durgam,suresh.durgam@actavis.com,falscher Kontakt Allergan kontaktiert,noch keine Antwort von Allergan erhalten,Durgam2015,control,weightextraction,change
331,NCT01104766a,699,2015,Aripiprazole,152,,,,,,Durgam2015,active,weightextraction,change
331,NCT01104766b,76206,2015,Cariprazine,312,,,,,,Durgam2015,active,weightextraction,change
978,Lieberman 2015,3198,2015,Placebo,85,"Lieberman JA, Davis RE, Correll CU et al.ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial. Biol Psychiatry2015",Dr Vanover,kvanover@intracellulartherapies.com,,,Lieberman2015,control,weightextraction,change
978,Lieberman 2015,3199,2015,Risperidone,82,,,,,,Lieberman2015,active,weightextraction,change
1033,Kane 2015,3340,2015,Placebo,184,,,,,,Kane2015a,control,weightextraction,change
1033,Kane 2015,76209,2015,Brexpiprazole,370,,,,,,Kane2015a,active,weightextraction,change
1056,Correll 2015,3392,2015,Placebo,184,,,,,,Correll2015,control,weightextraction,change
1056,Correll 2015,76210,2015,Brexpiprazole,362,,,,,,Correll2015,active,weightextraction,change
1406,NCT01098110,4158,2015,Placebo,174,"Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in asian patients with an acute exacerbation of schizophrenia: A multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology2016",Dr Kinoshita,kinoshit@takii.kmu.ac.jp,,,Kinoshita2016,control,weightextraction,change
1406,NCT01098110,76211,2015,Asenapine,358,,,,,,Kinoshita2016,active,weightextraction,change
1408,NCT01617187a,4163,2015,Asenapine,113,"Landbloom R, Mackle M, Wu X et al.Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr2016",Dr McIntyre,roger.mcintyre@uhn.ca,,,Landbloom2017,active,weightextraction,change
1408,NCT01617187a,4165,2015,Placebo,103,,,,,,Landbloom2017,control,weightextraction,change
1408,NCT01617187b,4164,2015,Olanzapine,46,,,,,,Landbloom2017,active,weightextraction,change
1415,NCT00905307a,4180,2015,Aripiprazole,50,"Kane JM, Skuban A, Hobart M et al.Overview of short-and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research2016",Dr Kane,JKane2@NSHS.edu,,,Kane2016,active,weightextraction,change
1415,NCT00905307a,4185,2015,Placebo,95,,,,,,Kane2016,control,weightextraction,change
1415,NCT00905307b,4183,2015,Brexpiprazole,90,,,,,,Kane2016,active,weightextraction,change
3017,Loebel 2015a,7985,2015,Lurasidone,199,"Loebel A, Silva R, Goldman R et al.Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry2016",Dr Loebel,antony.loebel@sunovion.com,,,Loebel2016,active,weightextraction,change
3017,Loebel 2015a,8166,2015,Placebo,112,,,,,,Loebel2016,control,weightextraction,change
280,Litmann 2014,591,2014,Placebo,41,"Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist azd2624 does not improve symptoms or cognition in schizophrenia: A proof-of-principle study. Journal of clinical Psychopharmacology2014",Dr Litman,relitman@cbhhealth.com,,,Litman2014,control,weightextraction,change
280,Litmann 2014,590,2014,Olanzapine,22,,,,,,Litman2014,active,weightextraction,change
394,Schmidt 2014,836,2014,Olanzapine,93,,,,,,Schmidt2014,active,weightextraction,change
601,Shen 2014,2965,2014,Placebo,78,"Shen JH, Zhao Y, Rosenzweig-Lipson S et al.A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research2014",Dr Williamns,jwilliams@medavante.com,,,Shen2014,control,weightextraction,change
601,Shen 2014,2964,2014,Olanzapine,77,,,,,,Shen2014,active,weightextraction,change
649,Durgam 2014a,2423,2014,Placebo,151,,,,,,Durgam2014,control,weightextraction,change
649,Durgam 2014a,2424,2014,Risperidone,140,"Durgam S, Starace A, Li D et al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase ii, randomized clinical trial. Schizophrenia Research2014",Dr Durgam,suresh.durgam@frx.com,,,Durgam2014,active,weightextraction,change
649,Durgam 2014b,76207,2014,Cariprazine,438,,,,,,Durgam2014,active,weightextraction,change
674,Geffen 2012,2476,2012,Risperidone,91,"Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study. Journal of clinical Psychiatry2012",Dr Geffen,yg@avphar.com,falscher Kontakt: neuer Kontakt: Michael.Davidson@sheba.health.gov.il,,Geffen2012,active,weightextraction,
674,Geffen 2012,2475,2012,Placebo,93,,,,,,Geffen2012,control,weightextraction,
245,Kinon 2011,505,2011,Olanzapine,62,"Kinon BJ, Zhang L, Millen BA et al.A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of ly2140023 monohydrate in patients with dsm-iv schizophrenia. Journal of clinical Psychopharmacology2011",Dr Kinon,Kinon_Bruce@Lilly.com,,,Kinon2011,active,weightextraction,change
245,Kinon 2011,506,2011,Placebo,122,,,,,,Kinon2011,control,weightextraction,change
235,Kane 2010a,483,2010,Haloperidol,115,"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical Psychopharmacology2010",Dr Kane,JKane2@NSHS.edu,,,Kane2010,active,weightextraction,change
235,Kane 2010a,484,2010,Placebo,123,,,,,,Kane2010,control,weightextraction,change
235,Kane 2010b,482,2010,Asenapine,220,,,,,,Kane2010,active,weightextraction,change
403,Study 006,902,2010,Lurasidone,99,,,,,,Ogasa2013,active,weightextraction,change
403,Study 006,903,2010,Placebo,50,,,,,,Ogasa2013,control,weightextraction,change
404,Study 049a,904,2010,Haloperidol,73,,,,,,Potkin2015,active,weightextraction,change
404,Study 049a,906,2010,Placebo,72,,,,,,Potkin2015,control,weightextraction,change
404,Study 049b,905,2010,Lurasidone,140,,,,,,Potkin2015,active,weightextraction,change
891,Study 196,2996,2010,Placebo,90,,,,,,Nakamura2009,control,weightextraction,change
891,Study 196,2995,2010,Lurasidone,90,,,,,,Nakamura2009,active,weightextraction,change
892,Study 229,2997,2010,Lurasidone,372,,,,,,Nasrallah2013,active,weightextraction,change
892,Study 229,2998,2010,Placebo,128,,,,,,Nasrallah2013,control,weightextraction,change
893,Study 231a,3001,2010,Placebo,116,,,,,,Meltzer2011,control,weightextraction,change
893,Study 231a,3000,2010,Olanzapine,123,,,,,,Meltzer2011,active,weightextraction,change
893,Study 231b,2999,2010,Lurasidone,239,,,,,,Meltzer2011,active,weightextraction,change
894,Study 233a,3003,2010,Placebo,122,,,,,,Harvey2013,control,weightextraction,change
894,Study 233a,3004,2010,Quetiapine,120,,,,,,Harvey2013,active,weightextraction,change
894,Study 233b,3002,2010,Lurasidone,246,,,,,,Harvey2013,active,weightextraction,change
163,Garcia 2009,324,2009,Haloperidol,60,"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs2009",Dr Nakamura,hiroshi-nakamura@ds-pharma.co.jp,,Daten erhalten,Garcia2009,active,weightextraction,
163,Garcia 2009,325,2009,Placebo,64,,,,,,Garcia2009,control,weightextraction,
190,Hera 041-021a,383,2009,Asenapine,208,"SH. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine postive control in subjects with an acute exacerbation of schizophrenia. Center for drug evaluation and research",Dr McIntyre,roger.mcintyre@uhn.ca,,,Hera2009a,active,weightextraction,
190,Hera 041-021a,385,2009,Placebo,106,,,,,,Hera2009a,control,weightextraction,
190,Hera 041-021b,384,2009,Olanzapine,103,,,,,,Hera2009a,active,weightextraction,
191,Hera 041-022,387,2009,Olanzapine,93,,,,,,Hera2009b,active,weightextraction,
191,Hera 041-022,388,2009,Placebo,93,,,,,,Hera2009b,control,weightextraction,
65,Casey 2008,146,2008,Risperidone,120,"Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology2008",Dr Casey,caseyd@ohsu.edu,,hat keine Daten,Casey2008,active,weightextraction,change
65,Casey 2008,145,2008,Placebo,119,,,,,,Casey2008,control,weightextraction,change
633,Cutler 2008a,2382,2008,Ziprasidone,151,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightextraction,change
633,Cutler 2008a,2299,2008,Placebo,152,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,control,weightextraction,change
633,Cutler 2008b,2298,2008,Iloperidone,303,,,,,"hat keine Daten, nochmals Rückfrage gestellt",Cutler2010,active,weightextraction,change
722,Johnson NCT00397033,2590,2008,Paliperidone,209,"Canuso C, Lindenmayer JP, Carothers J, Kosik-Gonzalez C, Turkoz I, Schooler N. Randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone er in the treatment of subjects with schizoaffective disorder. Biological Psychiatry2009",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010a,active,weightextraction,change
722,Johnson NCT00397033,2591,2008,Placebo,107,,,,,,Canuso2010a,control,weightextraction,change
723,Johnson NCT00412373,2593,2008,Placebo,95,"Canuso CM, Schooler N, Carothers J et al.Paliperidone extended-release in schizoaffective disorder: A randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of clinical Psychopharmacology2010",Dr Canuso,CCanuso@its.jnj.com,,,Canuso2010b,control,weightextraction,change
723,Johnson NCT00412373,2592,2008,Paliperidone,216,,,,,,Canuso2010b,active,weightextraction,change
724,Johnson NCT00524043,2594,2008,Paliperidone,70,"Coppola D, Melkote R, Lannie C et al.Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo-and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacology Bulletin2011",Dr Coppola,dcoppol2@its.jnj.com,,,Coppola2011,active,weightextraction,change
724,Johnson NCT00524043,2595,2008,Placebo,65,,,,,,Coppola2011,control,weightextraction,change
776,Lindenmayer 2008,2710,2008,Quetiapine,267,,,,,,Lindenmayer2008,active,weightextraction,change
776,Lindenmayer 2008,2709,2008,Placebo,84,,,,,,Lindenmayer2008,control,weightextraction,change
895,Study 3000a,3007,2008,Placebo,127,,,,,,Potkin2008,control,weightextraction,change
895,Study 3000a,3005,2008,Haloperidol,124,,,,,,Potkin2008,active,weightextraction,change
895,Study 3000b,3006,2008,Iloperidone,124,,,,,,Potkin2008,active,weightextraction,change
899,Study 3004a,3015,2008,Placebo,156,,,,,,Potkin2008,control,weightextraction,change
899,Study 3004a,3014,2008,Iloperidone,154,,,,,,Potkin2008,active,weightextraction,mean change
899,Study 3004b,3016,2008,Risperidone,153,,,,,,Potkin2008,active,weightextraction,change
900,Study 3005a,3019,2008,Risperidone,157,"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of clinical Psychopharmacology2008",Professor Potkin,sgpotkin@uci.edu,,,Potkin2008,active,weightextraction,
900,Study 3005a,3018,2008,Placebo,160,,,,,,Potkin2008,control,weightextraction,
900,Study 3005b,3017,2008,Iloperidone,389,,,,,,Potkin2008,active,weightextraction,
965,Study RGH-MD-03,3162,2008,Placebo,130,"Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. International clinical Psychopharmacology2016",Dr Durgam,moc.sivatca@magrud.hserus,,,Durgam2016,control,weightextraction,change
965,Study RGH-MD-03,3160,2008,Cariprazine,128,,,,,,Durgam2016,active,weightextraction,change
992,Cutler 2008a,3239,2008,Placebo,117,"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone- controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of clinical Psychopharmacology 2008",Dr Curt Wolfgang,kontakt-de@vandapharma.com,unsicherer Kontakt,,Cutler2010,control,weightextraction,change
992,Cutler 2008a,76208,2008,Quetiapine,448,,,,,,Cutler2010,active,weightextraction,change
129,Davidson 2007a,255,2007,Placebo,123,"Davidson M, Emsley R, Kramer M et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone er): Results of a 6-week, randomized, placebo-controlled study.[Erratum appears in schizophr res. 2007 nov;96(1-3):273-4]. Schizophrenia Research2007",Dr Davidson,davidso@netvision.net.il,,,Davidson2007,control,weightextraction,change
129,Davidson 2007a,253,2007,Olanzapine,128,,,,,,Davidson2007,active,weightextraction,change
129,Davidson 2007b,254,2007,Paliperidone,125,,,,,,Davidson2007,active,weightextraction,change
227,Kahn 2007,464,2007,Placebo,118,"Kahn RS, Schulz SC, Palazov VD et al.Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. Journal of clinical Psychiatry2007",Dr Kahn,rkahn@umcutrecht.nl,,,Kahn2007,control,weightextraction,change
227,Kahn 2007,465,2007,Quetiapine,470,,,,,,Kahn2007,active,weightextraction,change
307,McEvoy 2007b,649,2007,Aripiprazole,206,"McEvoy JP, Daniel DG, Carson, W. H., Jr., McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007",Dr McEvoy,jpmcevoy@duke.edu,,,McEvoy2007,active,weightextraction,change
307,McEvoy 2007b,650,2007,Placebo,108,,,,,,McEvoy2007,control,weightextraction,change
313,Meltzer 2007a,661,2007,Placebo,149,"Meltzer HYBLMHJYPPSNA. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia: 11th international congress on schizophrenia research; 2007",,,keine Kontakte auffindbar,,Meltzer2007,control,weightextraction,change
313,Meltzer 2007a,662,2007,Risperidone,154,,,,,,Meltzer2007,active,weightextraction,change
734,Kane 2007b,2617,2007,Placebo,127,,,,,,Kane2007,control,weightextraction,change
734,Kane 2007b,2615,2007,Olanzapine,128,"Kane J, Canas F, Kramer M et al.Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophrenia Research2007",Dr Kane,JKane2@NSHS.edu,,,Kane2007,active,weightextraction,change
734,Kane 2007c,2616,2007,Paliperidone,375,,,,,,Kane2007,active,weightextraction,change
789,Marder 2007c,2739,2007,Placebo,110,,,,,,Marder2007,control,weightextraction,change
789,Marder 2007c,2738,2007,Paliperidone,224,,,,,,Marder2007,active,weightextraction,change
789,Marder 2007d,2737,2007,Olanzapine,110,,,,,,Marder2007,active,weightextraction,change
829,Patil 2007,2830,2007,Olanzapine,34,"Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial.[Erratum appears in nat med. 2007 oct;13(10):1264]. Nature Medicine 2007",Dr Schoepp,schoepp_darryle_d@lilly.com,falscher Kontakt neu: Dr Monn via rg,,Patil2007,active,weightextraction,change
829,Patil 2007,2831,2007,Placebo,63,,,,,,Patil2007,control,weightextraction,change
845,Potkin 2007d,2866,2007,Placebo,62,,,,,,Potkin2007,control,weightextraction,change
845,Potkin 2007d,2867,2007,Risperidone,60,,,,,,Potkin2007,active,weightextraction,change
845,Potkin 2007c,2865,2007,Asenapine,60,,,,,,Potkin2007,active,weightextraction,change
843,Potkin 2003a,2859,2003,Aripiprazole,202,,,,,,Potkin2003,active,weightextraction,change
843,Potkin 2003a,2860,2003,Placebo,103,,,,,,Potkin2003,control,weightextraction,change
843,Potkin 2003b,2861,2003,Risperidone,99,,,,,,Potkin2003,active,weightextraction,change
231,Kane 2002b,473,2002,Haloperidol,104,,,,,,Kane2002,active,weightextraction,change
418,Study 94202 2002a,940,2002,Aripiprazole,61,2002 S9. Center for drug evaluation and research. Application number 21-436. Medical review(s). http://wwwfdagov 2002,,,keine Kontakte auffindbar,,Study942022002,active,weightextraction,
418,Study 94202 2002a,942,2002,Placebo,64,,,,,,Study942022002,control,weightextraction,
418,Study 94202 2002b,941,2002,Haloperidol,63,,,,,,Study942022002,active,weightextraction,
405,Study 115 2000a,908,2000,Placebo,83,2000 S1. Center for drug evaluation and research approval package for application number 20-825. Medical review. http://wwwfdagov 2000,,,keine Kontakte auffindbar,,Study1152000,control,weightextraction,
405,Study 115 2000a,909,2000,Ziprasidone,164,,,,,,Study1152000,active,weightextraction,
405,Study 115 2000b,907,2000,Haloperidol,85,,,,,,Study1152000,active,weightextraction,
127,Daniel 1999,249,1999,Placebo,92,"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo- controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999; 20: 491–505",,,keine Kontakte auffindbar,,Daniel1999,control,weightextraction,median change
127,Daniel 1999,250,1999,Ziprasidone,104,,,,,,Daniel1999,active,weightextraction,median change
14,Arvanitis 1997a,31,1997,Placebo,51,"Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The seroquel trial 13 study group. Biological Psychiatry 1997; 42: 233–46",,,keine Kontakte auffindbar,,Arvanitis1997,control,weightextraction,change
14,Arvanitis 1997a,32,1997,Quetiapine,105,,,,,,Arvanitis1997,active,weightextraction,change
14,Arvanitis 1997b,30,1997,Haloperidol,52,,,,,,Arvanitis1997,active,weightextraction,change
611,Small 1997,2988,1997,Quetiapine,96,"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Archives of General Psychiatry 1997; 54: 549–57.",,,keine Kontakte auffindbar,,Small1997,active,weightextraction,
611,Small 1997,2987,1997,Placebo,96,,,,,,Small1997,control,weightextraction,
946,Zimbroff 1997a,3123,1997,Sertindole,144,"Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997; 154: 782–91",Dr Zimbroff,dan.zimbroff@pcrmg.com,"verstorben, neuer Kontakt : danieldb@jmu.edu",,Zimbroff1997,active,weightextraction,no usable data
946,Zimbroff 1997a,3122,1997,Placebo,73,,,,,,Zimbroff1997,control,weightextraction,
946,Zimbroff 1997b,3121,1997,Haloperidol,137,,,,,,Zimbroff1997,active,weightextraction,
31,Beasley 1996a,70,1996,Placebo,50,"Beasley, C. M., Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996",Dr Beasley,cmbeasleyj@lilly.com,,,Beasley1996a,control,weightextraction,change
31,Beasley 1996a,69,1996,Olanzapine,50,,,,,,Beasley1996a,active,weightextraction,change
32,Beasley 1996b,71,1996,Haloperidol,69,,,,,,Beasley1996b,active,weightextraction,change
32,Beasley 1996b,73,1996,Placebo,68,,,,,,Beasley1996b,control,weightextraction,change
32,Beasley 1996c,72,1996,Olanzapine,133,,,,,,Beasley1996b,active,weightextraction,change
560,Borison 1996,2271,1996,Placebo,55,"Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL study group. J Clin Psychopharmacol 1996",,,keine Kontakte auffindbar,,Borison1996,control,weightextraction,change
560,Borison 1996,2272,1996,Quetiapine,54,,,,,,Borison1996,active,weightextraction,change
923,van Kammen 1996,3070,1996,Sertindole,105,,,,,,VanKammen1996,active,weightextraction,change
923,van Kammen 1996,3069,1996,Placebo,48,,,,,,VanKammen1996,control,weightextraction,change
942,Zborowski 1995a,3113,1995,Placebo,116,,,,,,Zborowski1995,control,weightextraction,change
942,Zborowski 1995a,3112,1995,Haloperidol,115,"Zborowski J, Schmitz P, Staser J et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995",Dr Tamminga,carol.tamminga@utsouthwestern.edu,,,Zborowski1995,active,weightextraction,change
942,Zborowski 1995b,3114,1995,Sertindole,117,,,,,,Zborowski1995,active,weightextraction,change
84,Clark 1972a,191,1972,Chlorpromazine,19,"Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 1972",,,keine Kontakte auffindbar,,Clark1972,active,weightextraction,endpoint
84,Clark 1972a,193,1972,Placebo,18,,,,,,Clark1972,control,weightextraction,endpoint
84,Clark 1972b,192,1972,Loxapine,18,,,,,,Clark1972,active,weightextraction,endpoint
591,Clark 1970a,2326,1970,Chlorpromazine,15,"Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. clinical",,,"keine Kontakte auffindbar, Letztautor verstorben",,Clark1970,active,weightextraction,endpoint kg
591,Clark 1970a,2328,1970,Placebo,14,Pharmacology & Therapeutics 1970,,,,,Clark1970,control,weightextraction,endpoint
